Noopept

• CAT Number: I001994
• CAS Number: 157115-85-0
• Molecular Formula: C17H22N2O4
• Molecular Weight: 318.4
• Purity: ≥95%
• Target: AMPAR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1
• InChIKey: PJNSMUBMSNAEEN-AWEZNQCLSA-N
• SMILES: O=C(CC1=CC=CC=C1)N2[C@H](C(NCC(OCC)=O)=O)CCC2

Noopept (GVS-111) is a medication promoted and prescribed in Russia and neighbouring countries as a nootropic.IC50 Value:Target:in vitro: Nooglutil exhibits pharmacologically significant competition with a selective agonist of AMPA receptors ([G-3H]Ro 48-8587) for the receptor binding sites (with IC50 = 6.4 +/- 0.2 microM), while the competition of noopept for these receptor binding sites was lower by an order of magnitude (IC50 = 80 +/- 5.6 microM) [1]. GVS-111 significantly increased neuronal survival after H(2)O(2)-treatment displaying a dose-dependent neuroprotective activity from 10 nM to 100 microM, and an IC(50) value of 1.21+/-0.07 microM. GVS-111 inhibited the accumulation of intracellular free radicals and lipid peroxidation damage in neurons treated with H(2)O(2) or FeSO(4), suggesting an antioxidant mechanism of action [2].in vivo: N-Phenylacetyl-L-prolylglycine ethyl ester (GVS-111) administered intravenously at a dose of 0.5 mg/kg/day, for the first time 1 h after ischaemic lesion and then for 9 post-operative days, with the last administration 15 min before testing, attenuated the deficit [3]. GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection (LOD) under high performance liquid chromatography (HPLC) conditions [4]. The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively) [5].Toxicity: Noopept administered in this dose range induced no irreversible pathologic changes in the organs and systems studied and exhibited no allergenic, immunotoxic, and mutagen activity [6].Clinical trial: Discontinued

Reference

1:Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model. Antipova TA, Nikolaev SV, Ostrovskaya PU, Gudasheva TA, Seredenin SB.Bull Exp Biol Med. 2016 May;161(1):58-60. doi: 10.1007/s10517-016-3344-z. Epub 2016 Jun 6. PMID: 27265136 2:Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept. Vakhitova YV, Sadovnikov SV, Borisevich SS, Ostrovskaya RU, A Gudasheva T, Seredenin SB.Acta Naturae. 2016 Jan-Mar;8(1):82-9. PMID: 27099787 Free PMC Article3:Nootropic dipeptide noopept enhances inhibitory synaptic transmission in the hippocampus. Povarov IS, Kondratenko RV, Derevyagin VI, Ostrovskaya RU, Skrebitskii VG.Bull Exp Biol Med. 2015 Jan;158(3):349-51. doi: 10.1007/s10517-015-2759-2. Epub 2015 Jan 9. PMID: 25573367 4:Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB.J Biomed Sci. 2014 Aug 6;21:74. doi: 10.1186/s12929-014-0074-2. PMID: 25096780 Free PMC Article5:Noopept normalizes parameters of the incretin system in rats with experimental diabetes. Ostrovskaya RU, Zolotov NN, Ozerova IV, Ivanova EA, Kapitsa IG, Taraban KV, Michunskaya AM, Voronina TA, Gudasheva TA, Seredenin SB.Bull Exp Biol Med. 2014 Jul;157(3):344-9. doi: 10.1007/s10517-014-2562-5. PMID: 25065315 6:Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes. Ostrovskaya RU, Ozerova IV, Gudascheva TA, Kapitsa IG, Ivanova EA, Voronina TA, Seredenin SB.Bull Exp Biol Med. 2014 Jan;156(3):342-6. doi: 10.1007/s10517-014-2345-z. Epub 2014 Jan 15. PMID: 24771372 7:[The dynamics of behavioral and neuroreceptor effects after acute and long-term noopept administration in C57BL/6 and BALB/c mice]. Kovalev GI, Kondrakhin EA, Salimov RM, Neznamov GG.Eksp Klin Farmakol. 2014;77(12):3-9. Russian. PMID: 25739185 8:Efficiency of noopept in streptozotocin-induced diabetes in rats. Ostrovskaya RU, Ozerova IV, Gudascheva TA, Kapitsa IG, Ivanova EA, Voronina TA, Seredenin SB.Bull Exp Biol Med. 2013 Jan;154(3):334-8. PMID: 23484194 9:[An experimental study of the anti-inflammatory action of noopept and its effect on the level of cytokines]. Alekseeva SV, Kovalenko LP, Tallerova AV, Gudasheva TA, Durnev AD.Eksp Klin Farmakol. 2012;75(9):25-7. Russian. PMID: 23156084 10:Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity. Jia X, Gharibyan AL, Öhman A, Liu Y, Olofsson A, Morozova-Roche LA.J Mol Biol. 2011 Dec 16;414(5):699-712. doi: 10.1016/j.jmb.2011.09.044. Epub 2011 Oct 1. PMID: 21986202